Image source: Bayer
The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer expands its portfolio beyond contrast media, medical devices, software, and services.
With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution providerGerd Krueger
Gerd Krueger, Head of Radiology at Bayer Pharmaceuticals, said: ‘With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams.’
Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which provide assistance at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites’ workflow, and free up time for radiology staff.
The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection. Another area of application is the triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO), both of which can be associated with stroke. More disease-specific application packages will be added moving forward, the company announces. Bayer provides services around installation, configuration, and training of the platform and its applications. First launch markets will include the US and several European countries, with more regions to follow.
The company sees increasing demand for innovation powered by AI: aging populations and changing lifestyles are leading to an increase in chronic conditions such as cardiovascular disease and cancer. Consequently, the need for medical imaging to detect diseases, guide treatment decisions and support therapy planning is growing. AI is the technology to meet these challenges, Bayer concludes, as it comes with the value proposition to accelerate diagnosis and increase the throughput of radiological examinations.
More information: www.calantic.com